The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets

British Journal of Dermatology

Volumn 157, Issue 4, 2007, Pages 752-757

  Wenzel, J ^a   Zahn, S ^a   Mikus, S ^a   Wiechert, A ^a   Bieber, T ^a   Tuting T ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cutaneous lupus erythematosus; CXCL10; CXCL9; CXCR3; Interferon; T cell

Indexed keywords

CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON INDUCIBLE PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL INFILTRATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; ORTHOMYXOVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN LUPUS ERYTHEMATOSUS;

BIOPSY; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHEMOKINES, CXC; GTP-BINDING PROTEINS; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; SKIN; T-LYMPHOCYTE SUBSETS;

EID: 34548585456     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08137.x     Document Type: Article

References (35)

1. Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006 54 : 408 20.
2. Hooks JJ, Moutsopoulos HM, Geis SA et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979 301 : 5 8.
3. Dall'era MC, Cardarelli PM, Preston BT et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005 64 : 1692 7.
4. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991 115 : 178 83.
5. Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosus-like syndrome induced by alpha-interferon therapy. Eur J Med 1992 1 : 379.
6. Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem 1995 43 : 47 52.
7. Blomberg S, Eloranta ML, Cederblad B et al. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001 10 : 484 90.
8. Wenzel J, Uerlich M, Worrenkamper E et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 2005 153 : 1011 15.
9. Farkas L, Beiske K, Lund-Johansen F et al. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001 159 : 237 43.
10. Meller S, Winterberg F, Gilliet M et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005 52 : 1504 16.
11. Wenzel J, Worenkamper E, Freutel S et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005 205 : 435 42.
12. Flier J, Boorsma DM, van Beek PJ et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001 194 : 398 405.
13. Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001 28 : 1 23.
14. Kuhn A, Sonntag M, Lehmann P et al. Characterization of the inflammatory infiltrate and expression of endothelial cell adhesion molecules in lupus erythematosus tumidus. Arch Dermatol Res 2002 294 : 6 13.
15. Tebbe B, Mazur L, Stadler R et al. Immunohistochemical analysis of chronic discoid and subacute cutaneous lupus erythematosus - relation to immunopathological mechanisms. Br J Dermatol 1995 132 : 25 31.
16. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003 4 : 69 77.
17. Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002 3 : 710 17.
18. Horisberger MA. Interferon-induced human protein MxA is a GTPase which binds transiently to cellular proteins. J Virol 1992 66 : 4705 9.
19. Wenzel J, Tüting T. Identification of type I interferon associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol 2007 16 : 454 63.
20. Wenzel J, Henze S, Brahler S et al. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Exp Dermatol 2005 14 : 454 9.
21. Adam C, Thoua Y, Ronco P et al. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol 1980 40 : 373 82.
22. Braun D, Geraldes P, Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003 20 : 15 25.
23. Santiago-Raber ML, Baccala R, Haraldsson KM et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003 197 : 777 88.
24. Wenzel J, Proelss J, Wiechert A et al. CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. J Am Acad Dermatol 2007 56 : 648 50.
25. Liu L, Callahan MK, Huang D et al. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol 2005 68 : 149 81.
26. Loetscher M, Loetscher P, Brass N et al. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998 28 : 3696 705.
27. Weber F, Schmuth M, Fritsch P et al. Lymphocytic infiltration of the skin is a photosensitive variant of lupus erythematosus: evidence by phototesting. Br J Dermatol 2001 144 : 292 6.
28. Iijima W, Ohtani H, Nakayama T et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 2003 163 : 261 8.
29. Wenzel J, Wiechert A, Merkel C et al. IP10/CXCL10-CXCR3 interaction: a potential self-recruiting mechanism for cytotoxic lymphocytes in lichen sclerosus et atrophicus. Acta Derm Venereol (Stockh) 2007 87 : 112 17.
30. Drosera M, Facchetti F, Landolfo S et al. Role of soluble and cell surface molecules in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol 2006 24 : S7 13.
31. Popovic PJ, DeMarco R, Lotze MT et al. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol 2006 177 : 8701 7.
32. Krieg AM. TLR9 and DNA 'feel' RAGE. Nat Immunol 2007 8 : 475 7.
33. Erlandsson Harris H, Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004 34 : 1503 12.
34. Okada AA, Keino H, Fukai T et al. Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998 6 : 215 26.
35. Clark-Lewis I, Mattioli I, Gong JH et al. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003 278 : 289 95.